Exact Sciences (EXAS) Merger with Abbott Moving Forward After Shareholder Approval

Exact Sciences Corp. (NASDAQ:EXAS) is one of 15 stocks with the biggest hedge fund momentum, after gaining 31 hedge fund holders during the fourth quarter of 2025. On February 20, the company announced that its shareholders had approved the proposed merger with Abbott Laboratories. The decision was made at a special meeting held that day. Under the terms of the merger agreement, Abbott Laboratories will acquire Exact Sciences for $105 per share in cash, a transaction valued at approximately $21 billion in equity. Exact Sciences will merge with a subsidiary of Abbott Laboratories and become a wholly owned subsidiary of Abbott.

Of the 190,810,202 shares eligible to vote, 128,906,310 shares of Exact Sciences Corp. (NASDAQ:EXAS), or 67.56%, were represented in person or by proxy, constituting a quorum. The merger agreement proposal received 128,431,562 votes in favor, 386,941 votes against, and 87,807 abstentions. Completion of the merger remains subject to customary closing conditions, including regulatory approvals.

Exact Sciences Corp. (NASDAQ:EXAS) is a cancer screening and diagnostics company that offers a non-invasive screening test for the early detection of certain types of cancer.

While we acknowledge the potential of EXAS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 13 Hot Stocks to Buy with the Highest Upside Potential and 10 Best High-Upside Materials Stocks to Buy

Disclosure: None.  Follow Insider Monkey on Google News.